Table 3.
Comparison of PASI-75 Response Rate Between Subgroups Within the Same Drug
| Patients without Elevated LFTs at Baseline | Patients with Elevated LFTs at Baseline | |
|---|---|---|
| Medication | ||
| Adalimumab | ||
| PASI-75 response at 3 months (%) | 38.1 | 31.3 |
| Chi² | 0.37 | |
| p | 0.541 | |
| OR (95%-CI) | 1.19 (0.67–2.11) | |
| PASI-75 response at 6 months | 38.5 | 53.1 |
| Chi² | 1.52 | |
| p | 0.217 | |
| OR (95%-CI) | 0.72 (0.43–1.21) | |
| Secukinumab | ||
| PASI-75 response at 3 months | 65.7 | 42.2 |
| Chi² | 4.35 | |
| p | 0.037 | |
| OR (95%-CI) | 1.51 (1.01–2.24) | |
| PASI-75 response at 6 months | 60.6 | 36.7 |
| Chi² | 4.51 | |
| p | 0.034 | |
| OR (95%-CI) | 1.48 (1.01–2.18) | |
| Ixekizumab | ||
| PASI-75 response at 3 months | 67.7 | 63.6 |
| Chi² | 0.09 | |
| p | 0.756 | |
| OR (95%-CI) | 1.11 (0.57–2.14) | |
| PASI-75 response at 6 months | 71.4 | 72.7 |
| Chi² | 0.01 | |
| p | 0.919 | |
| OR (95%-CI) | 0.96 (0.47–1.95) | |
| Apremilast | ||
| PASI-75 response at 3 months | 10.0 | 17.2 |
| Chi² | 0.50 | |
| p | 0.476 | |
| OR (95%-CI) | 0.80 (0.46–1.36) | |
| PASI-75 response at 6 months | 31.3 | 27.8 |
| Chi² | 0.04 | |
| p | 0.824 | |
| OR (95%-CI) | 1.08 (0.52–2.22) | |
Notes: Chi-squared test and odds ratio as effect size to compare PASI-75 response between subgroups within the same drug.
Abbreviations: LFTs, liver function tests; PASI, Psoriasis Area and Severity Index; Chi², chi-square statistic; p, p-value of chi-square test; OR, odds ratio; 95%-CI, 95%-confidence interval.